In the July 30, 2022, Revolution Cancer International Molecular Tumor Board the gloves came off as the spotlight was shined on p53. The PMV Pharma pipeline, and their p53 Y220C activator, were highlighted.
Thereafter, an incredible presentation of an extensive stage small cell lung cancer patient with a p53 Y220C mutation was performed in the context of the COMET algorithm and treatment cartography. All presently FDA-approved small cell lung cancer treatments were discussed, including the data that led to their approval. Clinical trials in the small cell lung cancer space, and a treatment map for the patient presented were illustrated. Unmet needs in small lung cancer were emphasized, and the RCIMTB team presented new clinical trials to consider.
If that wasn't enough the RCIMTB took it up another level to discuss NINE liver cancer patients with a unique molecular profile. The COMET algorithm was used to develop specific treatment maps for stage 4 hepatocellular cancer (HCC) patients. Absolutely UNPRECEDENTED CLINICAL TRIAL IDEAS were freely offered to pharmaceuticals, clinical trialists, etc. Unmet needs were discussed in HCC, and drug development concerns surrounding p53 activators were illustrated.
NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD. Not MSK, MD Anderson, Johns Hopkins, Mayo, etc.
If you don't believe that, PLEASE SEE FOR YOURSELF.
This tumor board was hosted by:
Basem S. Goueli MD, PhD, MBA (co-host): CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel
Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.
Silambarasan Maskomani Ph.D. (co-host): Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.
It featured:
Csaba Gajdos MD: Professor of surgery and chair of hepatobiliarypancreatic surgery for the University of Buffalo
Omar Chohan MD: Interventional Radiologist and Associate Director of the Radiology residency program for the University of Buffalo
Bhadresh Rami Ph.D.: Senior Consultant and Advisor for Smagen
Ali Ucar: CEO and co-founder of CaresolutionsUSA
14 окт 2024
